Company Filing History:
8 out of 9 
8 out of 1,271 
Years Active: 2021-2025
Title: Greg Mayhew: Innovator in Cancer Research
Introduction
Greg Mayhew is a prominent inventor based in Durham, NC (US), known for his significant contributions to cancer research. With a total of 8 patents, he has developed innovative methods that enhance the understanding and treatment of various cancer subtypes.
Latest Patents
Among his latest patents are groundbreaking methods for subtyping bladder cancer. These methods and compositions allow for the determination of a subtype of Muscle Invasive Bladder Cancer (MIBC) in individuals by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for MIBC. Additionally, these methods provide insights into the response of individuals with a MIBC subtype to therapies such as immunotherapy. Another notable patent focuses on lung adenocarcinoma, where methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) by detecting the expression level of classifier biomarkers. This innovation also aids in assessing the response of individuals with adenocarcinoma subtypes to immunotherapy.
Career Highlights
Greg Mayhew has worked with notable organizations, including Genecentric Therapeutics, Inc. and the University of North Carolina at Chapel Hill. His work in these institutions has been pivotal in advancing cancer research and developing therapeutic strategies.
Collaborations
Throughout his career, Greg has collaborated with esteemed colleagues such as Hawazin Faruki and Myla Lai-Goldman, contributing to a rich exchange of ideas and innovations in the field of cancer research.
Conclusion
Greg Mayhew's innovative work in cancer research, particularly in the subtyping of bladder cancer and lung adenocarcinoma, showcases his commitment to improving patient outcomes through advanced therapeutic methods. His contributions continue to influence the landscape of cancer treatment and research.